Passage Bio Inc

NASDAQ:PASG   3:59:59 PM EDT
4.48
-0.41 (-8.38%)
Products, Regulatory

Passage Bio Announces Pipeline Expansion And Clinical Program Update

Published: 12/08/2021 12:29 GMT
Passage Bio Inc (PASG) - Passage Bio Announces Pipeline Expansion and Clinical Program Update.
Passage Bio Inc - Plan to Report Initial Data From Global Phase 1/2 Trial for Pbgm01 for Treatment of Infantile Gm1 Before Year End.
Passage Bio Inc - Expect to Dose First Patients in Global Phase 1/2 Trials for Frontotemporal Dementia and Krabbe Disease in Early 2022.
Passage Bio Inc - Exercised Two Additional Options With University of Pennsylvania's Gene Therapy Program.